Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Advances Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of pancreatic adenocarcinoma, confirmed by histology or cytology, in patients not suitable for pancreatic tumor resection with curative intent.
A diagnosis of recurrent pancreatic adenocarcinoma (previously confirmed by histology or cytology) in patients who have had a primary tumor resection.
Male or female patients over 18 years of age.
Laboratory values within the following ranges at screening:
Serum creatinine \< 1.25 times upper limit of normal (ULN) Haemoglobin \> 9.5 g/dL White blood cell (WBC) count \> 3.5 x 109/L Platelets \> 100 x 109/L Total bilirubin \< 2.0 times ULN Aspartate transaminase (AST, SGOT) \< 3 times ULN
A life expectancy of at least 2 months.
A negative pregnancy test at the screening visit (females of childbearing potential only).
Signed written informed consent.
You may not be if
History of other malignant disease (except basal cell carcinoma or in situ carcinoma of the uterine cervix).
Use of systemic (oral or injected) immunosuppressants, including corticosteroids, within 30 days prior to the baseline visit. Inhaled corticosteroids for chronic obstructive pulmonary disease or asthma were permitted.
Females of child bearing potential who are pregnant, lactating, or who are planning to become pregnant during the period of the study.
Participation in another study involving an investigational drug within 90 days of baseline.
Clareo Health | An Open Label Study to Evaluate G17DT Compared to Gemcitabine
